Background--Hemodialysis patients are at risk of intradialytic hypotension (IDH), which is associated with mortality and cardiovascular and neurological events. The use of biomarkers of volemia such as relative change in protidemia and BNP (B-natriuretic peptide) levels to predict IDH remains unknown.
I ntradialytic hypotension (IDH) is a frequent complication occurring in 20% to 30% of hemodialysis (HD) sessions. 1, 2 The National Kidney Foundation defines IDH as a decrease in systolic blood pressure (BP) by >20 mm Hg or a decrease in mean arterial pressure of 10 mm Hg associated with symptoms. 3 Although various definitions of IDH are used across different studies, it is uniformly associated with cardiovascular events, cardiac dysfunction, low-dose dialysis, vascular access thrombosis, deterioration of residual kidney function, brain atrophy, hospitalization, and mortality. 1, [4] [5] [6] [7] [8] The latter is most often observed in relation to the nadir of BP and the presystolic BP stratification. 8 Therefore, prevention of IDH could improve outcomes in these patients and should be part of each dialysis session assessment.
Several clinical risk factors have already been identified including age, longer dialysis vintage, left-ventricular diastolic dysfunction, lower predialysis BP, lower albumin, lower body mass index, higher ultrafiltration volume, and diabetes mellitus. 6, 7, 9 The search for biomarkers to detect IDH has been disappointing. For example, some studies have suggested that the BNP or N-terminal proBNP (brain natriuretic peptide or N-terminal pro-B-type natriuretic peptide) may represent a marker of fluid overload. 10, 11 However, the average BNP change during hemodialysis sessions failed to predict IDH. 12 Other biomarkers for IDH have been suggested in other studies such as magnesium variations or copeptin levels. 13, 14 Finally, the monitoring of blood hemoconcentration during dialysis by an external optical device emerged as a promising tool. Blood volume-monitoring measures track changes in total protein or hemoglobin at the arterial line during hemodialysis. However, results from several trials involving different blood volume monitoring manufacturers showed discrepant results for the prevention of IDH. 15, 16 Interestingly, the evaluation of blood concentration in blood samples reflected by the relative change of protidemia level, defined by Dprotidemia (postdialysis protidemiaÀpredialysis protidemia), has not been evaluated to predict IDH.
In the present study we evaluated whether BNP and Dprotidemia measured on the monthly blood test could predict the 30-day risk of IDH. We showed that Dprotidemia was the best predictor for 30-day risk of IDH.
Methods

Data Sharing
The data that support the findings of this study are available from the corresponding author on reasonable request (Contact M.T., maxime.touzot@auraparis.org).
Patients
We initiated a single-center, observational, prospective study of adult HD patients (>18 years old) over a 6-month period (September 2015 to March 2016). All consecutive adults in chronic hemodialysis in AURA Paris Plaisance center were reviewed. Inclusion criteria were (1) patient on hemodialysis >6 months and (2) 6 consecutive monthly measures of BNP and protidemia before and after dialysis.
Data Collection
We collected patient epidemiological and laboratory data using our medical informatics record system (Hemodial, PHP Development, LOOS, France).
Demographic data collected were age, sex, ethnicity, initial nephropathy, diabetes mellitus, coronary artery disease, HD vintage, HD technique (hemodiafiltration or hemodialysis), dialysis efficacy assessed by clearance9time/volume of distribution, and use of antihypertensive drugs (b-blocker, renin angiotensin aldosterone system blocker, calcium channel blocker). Clinical events during the observational period were also collected: uncontrolled hypertension (defined as BP above 140/90 mm Hg on repeated measures despite good adherence to triple antihypertensive therapy and adjustment of dialysis dry weight), IDH (defined by a >20 mm Hg drop in systolic blood pressure with symptoms of dizziness, nausea, vomiting, blurred vision, cramps or syncope during the dialysis session, acute pulmonary edema, need for hospitalization), acute coronary syndrome (negative ST-elevation myocardial infarction), stroke, de novo atrial fibrillation, acute limb ischemia, acute mesenteric ischemia, and death. Clinical dialysis parameters were also collected: systolic and diastolic BP pre-and postdialysis (measured by the nurse and recorded in our medical record), dry weight and interdialytic weight gain.
In AURA Paris Plaisance, all patients have monthly blood tests such as pre-and postdialysis ionograms, and hemoglobin level measurements. We used the postdialysis protidemiaÀpredialysis protidemia difference to define the Dprotidemia. Albumin levels were measured every 3 months. BNP levels are routinely measured each month on routine blood tests since 2014 due to our local practice. BNP levels as well as the other laboratory parameters are performed before dialysis at the midweek session. Midweek measures were used to standardize results, as this leads to a relatively constant BNP level. 17 BNP was measured by immunoassay on an Architect i2000 (Abbot Diagnostics, Lake Forest, IL). BNP levels <100 ng/L are considered normal in non-chronic kidney disease, and the detection limits range from 20 to 5000 ng/L.
In AURA Paris Plaisance, every patient has an annual cardiovascular evaluation that includes echocardiography. Data for echocardiography were analyzed if available during the year of the study. Echocardiography was performed on a nondialysis day during the year of the study. Left ventricular mass index, left ventricular ejection fraction, and left atrial enlargement were measured by standard techniques.
Ethical Statement
Our study is a prospective human noninterventional study. According to the Public Health French Law (art L 1121-1-1, art L 1121-1-2), approval from an institutional review board and written consent are not required for human noninterventional studies.
Clinical Perspective
What Is New?
• The relative change in protidemia level or Dprotidemia=postdialysis protidemiaÀpredialysis reflects hypovolemia in dialysis patients. • DProtidemia outperforms brain natriuretic peptide level or the ultrafiltration rate as a predictor for 30-day risk of intradialytic hypotension. • DProtidemia of 10 g/L allowed for discrimination of the patients with intradialytic hypotension.
What Are the Clinical Implications?
• DProtidemia might serve as a surrogate marker of hypovolemia for dry weight adjustment. • Prospective studies are needed to confirm its use for dry weight management. To take into account the longitudinal nature of the study, we fitted a logistic mixed model using the glmer function from the lme4 package (version 1.1-15) of R, using a subjectspecific random intercept. Distribution of Dprotidemia was considered normal as opposed to that of BNP, which was positively skewed ( Figure S1 ). Due to a right-skewed distribution, log(BNP) was used instead of BNP in the multimodel analysis. DProtidemia was not transformed for the analysis.
Statistical Analyses
Receiver operating characteristic analysis was performed using the ROC.curv (version 1.0-7) function also implemented in R software.
Results
Over the 6-month period, 170 chronic hemodialysis patients were recruited for the study. Baseline demographic and biological characteristics are listed in Table 1 . Briefly, the mean age of patients was 67AE16 years. Diabetes mellitus and coronary artery disease were observed in 38% and 29%, respectively. The median dialysis vintage was 44 months (range 19-79). Most patients (98%) were on hemodiafiltration. The median BNP level was 280 ng/L (range 121-697).
We hypothesized that the combination of clinical (systolic BP, IDH) and biological parameters (Dprotidemia and BNP) might help in identifying a specific phenotype. We used unsupervised analysis based on the 6 monthly measures of Dprotidemia, BNP, systolic BP, and the occurrence of IDH ( Figure 1 ). Hierarchical clustering identified 3 groups: G1 (N=60), G2 (N=54), and G3 (N=56), respectively. Baseline demographic and biological characteristics are also listed in Table 1 .
Patients were older in G1 (71AE13 versus 66AE15 in G2 and 63AE18 in G3 [P=0.017]) and were slightly more likely to be white (62% versus 35% and 52%, P=0.018). G1 patients had a higher left atrial enlargement surface >20 cm 2 (41% versus 11% and 24% in G2 and G3, respectively, P=0.002). Median BNP was significantly higher in G1 than in the other groups: 895 (interquartile range 516-1373) versus 222 (interquartile range 104-365) and 157 (interquartile range 102-267) ng/L in G2 and G3, respectively (P<0.001). Mean Dprotidemia was lower in G1 than in the other groups (3.4AE4.1 versus 7.7AE3.8 and 9.7AE5.4 g/L; P<0.001). There was no difference in terms of type of nephropathy, cardiovascular risk factors, left ventricular ejection fraction, left ventricular mass index, aortic stenosis, and type of antihypertensive drugs among the 3 groups.
Dialysis Parameters
There was no difference in dialysis modes among the groups ( Table 1 ). Postdialysis systolic BP was significantly lower in G3 (128AE16 versus 145AE24 and 150AE15 mm Hg in G3, G1, G2, respectively; P<0.001). The ultrafiltration rate (UFR), measured on the day of the blood sample, was slightly higher in G3 (11AE4) compared with G1 (9AE5) and G2 (10AE4), respectively, which were not significantly different statistically. Predialysis diastolic and systolic BP, and postdialysis diastolic BP were also significantly lower in G3. There was no difference among groups in terms of dialysis vintage, intradialytic weight gain, albumin plasma level, hemoglobin, and dialysis efficacy assessed by the clearance9time/volume of distribution (Table 1) .
Clinical Events
During the 6-month observational study, IDH occurred in 74 out of 121 patients, and the rate was highest for the G3 patients ( Table 2) . We evaluated the incidence of IDH during the first 3 months of the study in the 3 groups ( Figure 2 ). We chose the 90-day period because Dprotidemia was quite constant during this period for all 3 groups (data not shown). G3 Patients experienced more IDH (58%) compared with patients from groups 1 (23%) and 2 (19%), respectively (P<0.0001), during the 90-day observation period. No difference in IDH was observed between G1 and G2 patients (P=0.76) ( Figure 2 ). Nine patients had de novo atrial fibrillation, mostly in the G1 group (N=6, P=0.037). Atrial fibrillation was diagnosed during the dialysis session. The greater proportion of patients with left atrial enlargement (>20 cm 2 ) in the G1 group may partially explain this finding. Finally, there was no significant difference among groups in terms of acute pulmonary edema, cardiovascular events, supplementary dialysis sessions, or hospitalization during the study period ( Table 2 ).
Biological Markers as Predictors for 30-Day Risk of IDH
To evaluate the performance of Dprotidemia and BNP to predict the 30-day risk for IDH, we used a logistic mixed model that takes into account the longitudinal structure of the data (see Patients and Methods). Distribution of Dprotidemia was considered normal as opposite to that of BNP, which was positively skewed ( Figure S1 ). LogBNP was used instead of BNP in the logistic mixed model. We included the following variables in the model that contributed to IDH: Dprotidemia, logBNP, age, and UFR. Only Dprotidemia was statistically associated with the 30-day risk of IDH with odds ratio=1.12, 95% CI 1.08-1.17, but not with BNP with odds ratio=0.81, 95% CI 0.64-1.07. UFR was not associated with IDH, odds ratio=1.1, 95% CI 0.95-1.09; P=0.573. The odds ratios were consistent after inclusion or removal of UFR. Only the model without it is presented here ( Table 3 ).
Defined Specific Threshold for DProtidemia
Finally, we used the area under the receiver operating curves (AUC) to define a specific threshold in order to discriminate patients at risk of IDH (Table 4 ). In all patients Dprotidemia of 10 g/L allows this discrimination with an AUC of 0.67 (95% CI 0.62-0.72, sensitivity=0.53, specificity=0.70). To increase the robustness of this model, we stratified patients according to the presence of cardiac disease (=presence of coronary artery disease and/or atrial fibrillation), diabetes mellitus, and BNP (> or <300 ng/L). The AUC was slightly increased when BNP was used for stratification, but the cutoff remained similar. When BNP was under 300 ng/L, the AUC was 0.71 (95% CI 0.63-0.76, sensitivity=0.57, specificity=0.71) for a cutoff value of 11 g/L. When the BNP was above 300 ng/L, the AUC was 0.69 (95% CI 0.542-0.69, sensitivity=0.58, speci-ficity=0.68) for a cutoff value of 10 g/L. Surprisingly, the cutoff value was much lower (2 g/L) for diabetes mellitus patients despite a similar AUC.
Discussion
IDH is associated with poor outcomes for HD patients, and its prevention is key for clinicians caring for these patients. Although some nonmodifiable markers (eg, age) and underlying comorbidities have been associated with IDH, there are only few algorithms based on clinical or biological markers that can predict IDH, and no reliable predictive biomarkers are available. 9, 18 In the present study, using 3 different methods, we showed that the relative change in protidemia level (=Dprotidemia) measured during routine blood sampling is a potential biomarker to predict IDH that outperforms UFR. We identified a specific group of patients characterized by a high Dprotidemia and a low BNP that had the highest incidence of IDH during the 90-day observation period. Next, we used a logistic mixed model (that takes into account the repeated measures) and demonstrated that Dprotidemia was strongly associated with IDH, but not BNP or UFR, when adjusted for multivariables. Finally, we defined the specific threshold of Dprotidemia that identified patients at risk for IDH. The underlying mechanisms of IDH are complex. Although intravascular hypovolemia remains the major cause of IDH, impaired compensatory mechanisms are also involved. The latter includes cardiac responses to maintain cardiac output and venous return, arteriolar vasoconstriction, plasma refilling from the interstitial and extracellular components, and dysfunction of the sympathetic nervous system. 1, 19 Hypovolemia may be detected by changes in total protein and hemoglobin levels using external devices during the dialysis session. This concept leads to the development of blood volume monitoring to help clinicians and to improve fluid removal management. However, results of trials have shown conflicting results for IDH prevention due to the lack of standardization of protocols (eg, sodium biofeedback, computerized biofeedback) and the study duration. 15, 16, 20 Here, we used an alternative approach to estimate hypovolemia based on the variation of protidemia before/after dialysis. This Dprotidemia is a simple marker and available monthly at each blood test. Our results suggest that this measurement should be integrated in the decision process for dry weight adjustment. Table 1 represents data of the total population (N=170) and the subgroups G1, G2, and G3 identified by hierarchical clustering. All continuous values are expressed as meanAESD except for HD vintage and BNP, which are expressed as median and IQR (interquartile range). BNP indicates brain natriuretic peptide; CAD, coronary artery disease; dBP, diastolic blood pressure; HD vintage, hemodialysis vintage; HDF, hemodiafiltration; IDWG, intradialytic weight gain; Kt/V, clearance9time/volume of distribution (a measure of dialysis efficacy); LAE, left atrial enlargement >20 cm 2 ; LVEF, left ventricular ejection fraction; LVMI, left ventricular mass index; RAAS, renin-angiotensin-aldosterone system; sBP, systolic blood pressure; TIN, tubulointerstitial nephropathy; UFR, ultrafiltration rate. e   BNP_M4  BNP_M5  BNP_M2  BNP_M3  BNP_M0  BNP_M1  PAS_M0  PAS_M1  PAS_M2  PAS_M3  PAS_M4  PAS_M5  HypoPA  DeltaPROT_M4  DeltaPROT_M5  DeltaPROT_M2  DeltaPROT_M3  DeltaPROT_M0  DeltaPROT_M1   P12  P86  P22  P104  P15  P106  P107  P81  P99  P139  P129  P87  P138  P79  P156  P20  P166  P11  P161  P16  P144  P157  P119  P4  P168  P160  P55  P110  P101  P142  P103  P105  P170  P76  P164  P120  P136  P94  P35  P95  P115  P85  P130  P45  P97  P137  P72  P78  P52  P111  P151  P23  P46  P66  P155  P14  P80  P77  P58  P126  P51  P43  P100  P2  P131  P37  P98  P162  P147  P125  P42  P30  P159  P127  P54  P135  P50  P57  P116  P74  P167  P82  P88  P62  P17  P29  P65  P70  P146  P36  P134  P1  P64  P19  P114  P148  P169  P6  P152  P33  P93  P109  P26  P141  P34  P32  P38  P140  P133  P67  P63  P83  P108  P56  P25  P8  P113  P40  P154  P49  P163  P117  P73  P90  P89  P165  P112  P69  P18  P27  P24  P102  P44  P7  P48  P60  P53  P92  P21  P68  P118  P145  P158  P28  P121  P96  P123  P124  P59  P71  P153  P13  P122  P128  P31  P132  P91  P39  P41  P143  P10  P75  P47  P149  P9  P3  P84  P5 Our results may not apply to all diabetes mellitus patients. Indeed, according to the receiver operating characteristic curve analysis, diabetes mellitus patients are at risk of IDH when the Dprotidemia is >2 g/L versus 10 g/L for nondiabetic patients. This level cannot be considered as a true hemoconcentration. However, this lower value for Dprotidemia probably reflected another cause of IDH, which is dysautonomia-related IDH. Diabetes mellitus patients are at increased risk of peripheral neuropathy including dysautonomia. Adequate sympathetic nervous system activation is essential for the compensatory mechanisms of BP maintenance during the HD procedure. 21 However, this mechanism is altered in diabetes mellitus patients. Thus Dprotidemia may not be used for diabetes mellitus patients with dysautonomia.
Our study showed that, although BNP may be related to IDH in a bivariate model, the relationship does not hold when other variables are taken into account, and Δprotidemia remains the best predictor. Although we did not test the variation in mean BNP as previously described, 12 we could not find a threshold of BNP at risk for IDH. Several explanations may account for this negative result. First, it is still controversial as to whether BNP reflects fluid overload or only left ventricular dysfunction. 22, 23 Second, BNP levels in HD are influenced by many factors independent of fluid status. We recently reported a mathematical model to predict BNP levels in HD according to 6 biological and clinical variables. 24 Whether the use of the predicted versus Table 2 represents clinical events for the total population (N=170) and the subgroups G1, G2, and G3 identified by hierarchical clustering. Percentages reported are of the total number of events. P-values are for ANOVA comparing G1, G2, and G3. NA indicates not applicable. G1 G2 G3 Figure 2 . Cumulative incident risk for IDH. The graph represents the cumulative incidence risk for intradialytic hypotension (IDH) during the first 90 days of the study according to the 3 groups. The difference was statistically significant between G3 and G1 or G2, respectively (P<0.001, log-rank test). Incidence of IDH was similar between G1 and G3 (P=0.67). measured BNP could predict IDH was not tested in our cohort due to missing data for 1 variable.
Our study has several limitations. First, it is a prospective single-center study without external validation, and the odds ratio obtained by our model is weak despite statistical significance. However, it should be noted that several factors may have weakened our model, including some clinicians in our institution already using the Dprotidemia in their personal algorithm for dry weight adjustment. Therefore, correction of dry weight partially based on high Dprotidemia and other markers may avoid the occurrence of IDH in the 30 days following the measure. Second, presence of dysautonomia in diabetes mellitus patients may have biased the hypovolemia-related IDH. Finally, most of our patients were on hemodiafiltration. It has been shown that risk of hypotension is lower in hemodiafiltration versus conventional hemodialysis. Whether our results and cutoff could be extrapolated to other patients in hemodialysis is unclear, but a similar trend is likely. Notwithstanding, our study has several strengths including the number of patients (N=170) and the use of 3 different statistical methods to evaluate our results.
To conclude, we report that the relative change in protidemia level, Dprotidemia, might serve as a surrogate marker of hypovolemia and predict the 30-day risk of IDH in HD. These results may not be applicable to diabetes mellitus patients due to dysautonomia. These results should be confirmed by a prospective study. We stratified patients according to the presence of CD (yes=1, no=0), diabetes mellitus (yes =1, no=0), and BNP (> or <300 ng/L). DProtidemia indicates =postdialysis protidemiaÀpredialysis protidemia; AUC, area under the receiver operating curves; BNP, brain natriuretic peptide; CD, cardiac disease (=presence of coronary artery disease and/or atrial fibrillation); ROC, receiver operating characteristic.
